Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02825459
Other study ID # 1R01CA192940-01
Secondary ID R01CA192940-01
Status Completed
Phase N/A
First received
Last updated
Start date July 2016
Est. completion date October 31, 2018

Study information

Verified date November 2018
Source University of Vermont
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to see whether adults who use e-cigarettes every day experience symptoms of nicotine withdrawal when they stop using e-cigarettes for 6 days.


Description:

Study Design: The investigators will recruit 120 individuals who are long-term daily and exclusive users of nicotine-containing e-cigarettes. Participants will be asked to use their own e-cigarette as usual during the first week of the study and to then stop their use of e-cigarettes for 6 days. The total study duration will be 14 days. Participants will be instructed to continue abstinence from other tobacco and nicotine products during the entire study. The investigators will use an escalating payment system with bonuses based on breath and urine samples to encourage compliance.

Every day during the study, participants will report e-cigarette and tobacco cigarette use and monitor symptoms of nicotine withdrawal via a phone call to an Interactive Voice Response system. Participants will attend 3 study visits each week to provide urine and breath samples to verify compliance, and to complete brief surveys.


Recruitment information / eligibility

Status Completed
Enrollment 147
Est. completion date October 31, 2018
Est. primary completion date October 31, 2018
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- 18 years or older

- Able to read and understand verbal English fluently

- US citizen or resident alien

- Primarily uses e-cigarette product types of refillable tanks or modified devices

- Uses nicotine-containing e-liquid

- Has baseline urinary cotinine concentration of > 100 ng/ml

- Has used e-cigarettes daily for the last 2 months

- Has a home or cell phone

- Agrees to abstain from tobacco, marijuana and other illegal drugs during study

Exclusion Criteria:

- Smoked > 5 tobacco cigarettes in the last month

- Used non-cigarette nicotine, tobacco or quit smoking products on >5 days in the past month

- Use of cannabis (either marijuana or synthetic cannabis) > 5 times in the past month or positive test for cannabis use at screening

- Current (last 6 months) Generalized Anxiety Disorder, Major Depressive Disorder, Attention Deficit Hyperactivity Disorder or moderate/severe Substance Abuse Disorder

- Multiple legal, social health, work or school problems in the past month due to alcohol or drug use

- Pregnant or breastfeeding

- Previously a participant in the current study

- Use of prescribed or non-prescribed psychoactive medication > 5 times in the past month

- Expired carbon monoxide level > 8ppm

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Abstinence from e-cigarettes
Abrupt cessation for 6 days

Locations

Country Name City State
United States Battelle Memorial Institute Baltimore Maryland
United States University of Vermont Burlington Vermont

Sponsors (2)

Lead Sponsor Collaborator
University of Vermont National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Total score on the Minnesota Nicotine Withdrawal Scale (MNWS) The investigators will compare the mean score across participants for the entire 6-day abstinence vs. use conditions. 6 days
Secondary Individual items on the Minnesota Nicotine Withdrawal Scale (MNWS) The investigators will use the mean score for each of the 16 symptoms across participants during abstinence and use conditions. 6 days
Secondary Questionnaire of E-cigarette Urges (brief) This is a revision of the brief version Questionnaire of Smoking Urges that asks about urges for e-cigarettes rather than tobacco cigarettes. 6 days
Secondary Questionnaire of Smoking Urges- brief version This 2-item scale asks about intensity and frequency of urges. 6 days
Secondary Heart rate Measured for 30 sec after sitting for 15 minutes 6 days
Secondary E-cigarette Purchase Task This is a modification of the Cigarette Purchase Task that asks how much users would expend to obtain their usual amount of e-liquids to use. 6 days
See also
  Status Clinical Trial Phase
Completed NCT00114439 - Lithium Cannabis Withdrawal Study Phase 2
Completed NCT00980044 - Efficacy of Extended Release Tramadol for Treating Prescription Opioid Withdrawal Phase 2/Phase 3
Completed NCT02643355 - Utility of Olanzapine in the Treatment of Opioid Withdrawal in the ED N/A
Completed NCT02782156 - Process Evaluation Standardised Nurse-led Approach for Risk Screening and Decrease of Alcohol Withdrawal in ENT N/A
Recruiting NCT00792415 - Validation of a Pediatric-Specific Abstinence Syndrome Assessment Tool N/A
Completed NCT02431728 - The Effect of Melatonin Upon Post-Acute Withdrawal Among Males in a Residential Treatment Program Phase 1/Phase 2
Completed NCT00695864 - Effect of Ondansetron for Withdrawal Symptoms N/A
Active, not recruiting NCT02951793 - Abuse and Addiction in ICU
Completed NCT02108626 - Electronic Cigarettes in Daily Dependent Smokers Phase 4
Recruiting NCT04917185 - EA for PAAS: A pRCT N/A
Completed NCT02801357 - Study to Evaluate the Exposures of Lofexidine and Its Major Metabolites in Subjects Seeking Buprenorphine Dose Reduction Phase 1
Completed NCT01362959 - Nicotine Replacement Therapy in the Intensive Care Unit Phase 4
Completed NCT00992979 - Therapeutic Massage to Manage Withdrawal Related Anxiety Phase 2
Completed NCT00900900 - The Effects of One-Time Pregnenolone, Dehydroepiandrosterone (DHEA), or Placebo Administration On Withdrawal Symptoms, Mood, Craving And Cigarette Evaluation Ratings In Male Smokers Phase 2
Completed NCT02318290 - Opioids Withdrawal Syndrome in Critically Ill Patients: a Multicenter Prospective Cohort Study N/A
Completed NCT00032968 - Buprenorphine/Naloxone Versus Clonidine for Outpatient Opiate Detoxification - 1 Phase 3
Completed NCT03374722 - Opioid Withdrawal Symptoms in Critically Ill Patients
Completed NCT03435614 - Signs and Symptoms of Opioid-associated Iatrogenic Withdrawal in Critically Ill Adults
Completed NCT00570219 - The Effect of Valproate on Benzodiazepine Withdrawal Severity N/A
Completed NCT00367874 - Treatment of Polydrug-Using Opiate Dependents During Withdrawal Phase 4